From AI to zoonotic viruses, biotechnology discoveries are not only underpinning new treatments for disease but also generating revenue for the companies that grew from investor-driven startups to commercial-scale businesses having braved years of research, clinical, regulatory, and commercial hurdles. In GEN’s flagship virtual event, The State of Biotech—sponsored exclusively by Cytiva—outstanding research and business leaders from industry and academia will discuss the latest research developments, innovations, new technologies, and convulsive regulatory changes that are reshaping the world of biotech.

“The State of Biotech” features a keynote interview with George Church, PhD (Harvard Medical School), who will discuss his cutting-edge research that for more than four decades has generated discoveries and spawned dozens of companies in fields ranging from genomics and gene therapy to synthetic biology and de-extinction.

Iya Khalil, PhD, VP and Head of Data, AI and Genome Sciences with Merck & Co., will discuss how her company’s approach stands out in the increasingly crowded AI-based drug discovery field, as well as successful applications of the technology.

Also on the agenda:

The co-hosts of the popular Biotech Hangout podcast—Daphne Zohar, Brad Loncar, and Chris Garabedian—review the trends convulsing and reshaping biotech

The clinical successes and commercial struggles of gene editing therapies will be analyzed in a roundtable featuring Rodolphe Barrangou, PhD (North Carolina State University), Geulah Livshits, PhD (Chardan), and Amber Salzman, PhD (Epicrispr Biotechnologies)

The challenges and potential opportunities presented by recent shifts in federal policy—from agencies to funding—will be explored by Aiken Hackett (BIO) and Yvette R. Seger, PhD (FASEB)

The State of Biotech is GEN’s flagship virtual event. Registration is entirely free!